Nicholas P Casey, Katrin Kleinmanns, Christopher Forcados, Pascal F Gelebart, Sandy Joaquina, Martine Lode, Emmanuelle Benard, Fatemeh Kaveh, Benjamin Caulier, Christiane Helgestad Gjerde, Elvira García de Jalón, David J Warren, Kristina Lindemann, Erik Rokkones, Ben Davidson, Marit Renee Myhre, Gunnar Kvalheim, Line Bjørge, Emmet McCormack, Else Marit Inderberg, Sébastien Wälchli
BACKGROUND: Ovarian cancer (OC) is the leading cause of death from gynecologic malignancies in the Western world. Contributing factors include a high frequency of late-stage diagnosis, the development of chemoresistance, and the evasion of host immune responses. Currently, debulking surgery and platinum-based chemotherapy are the treatment cornerstones, although recurrence is common. As the clinical efficacy of immune checkpoint blockade is low, new immunotherapeutic strategies are needed...
April 11, 2024: Journal for Immunotherapy of Cancer